Építés alatt – nem éles oldal
Belépés
Résztvevőt keres1. fázis

A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy

A legfontosabb adatok

Ki végzi
H. Lundbeck A/S
Hol
Finnország2 helyszín, 1 országbanVálassz országot a helyszínekhez
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
104 fő, tervezett
Kezdés
2025. jún. 13.
Várható befejezés
2027. febr. 16.
A vizsgálat típusa
Beavatkozással járó, 4 csoport
A vizsgált kezelések
  • Lu AH69593
  • Placebo
A regiszteradat frissítve
2026. augusztus 12.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for healthy adults, and for adults with narcolepsy type 1 (NT1), to test the safety of Lu AH69593. It also looks at how food changes the way the body handles the drug.

Életkor
Healthy people: 18 to 55 years. People with NT1: 18 to 64 years.
Nem
All sexes can join.
A betegség stádiuma
Healthy people can join Parts A, B and D. Part C is for people with narcolepsy type 1 (NT1), diagnosed by ICSD-3 criteria more than 3 months before screening.
Korábbi kezelés
People who have already had Lu AH69593 cannot join.
Biomarker vagy leletérték
Resting pulse lying down of ≥45 and ≤100 beats per minute. BMI ≥18.5 and ≤30 kg/m^2 for healthy people, ≥18.5 and ≤35 kg/m^2 for people with NT1. Healthy people must have a normal sleep pattern: they wake up between 6:00 and 9:00 a.m. and go to sleep between 9:00 p.m. and midnight.

A részvétel fő kizáró okai

  • Being pregnant, breastfeeding, or planning a pregnancy. People who could become pregnant and will not use birth control also cannot join.
  • Cancer not in remission for more than 5 years, except some skin cancers and treated early cervical changes
  • Shift or night work, or travel across more than 3 time zones, in the 2 weeks before the first dose
  • Being in another clinical trial in the 30 days before screening, or training intensively, for example for marathons
  • High risk of suicide (Parts B and C), or for NT1 people, another illness that causes strong daytime sleepiness

A regiszter feltételei, szó szerint

Mind a 20 feltétel megnézéseKevesebb

Ki vehet részt

  • For all participants in any trial Part (A, B, C and D):
  • The participant has a resting supine pulse ≥45 and ≤100 beats per minute (bpm) at the Screening Visit and at the Baseline Visit; Specifically for participants in trial Part A, B, and D:
  • The participant has a body mass index (BMI) ≥18.5 and ≤30 kilograms (kg)/square meter (m\^2) at the Screening Visit
  • The participant has a normal circadian rhythm, defined as a person who usually wakes up between 6:00 and 9:00 a.m. and goes to sleep between 9:00 p.m. and midnight
  • The participant is ≥18 and ≤55 years of age at the Screening Visit; Specifically for participants in trial Part C:
  • The participant has a BMI ≥18.5 and ≤35 kg/m\^2 at the Screening Visit
  • The participant has NT1, diagnosed according to International Classification of Sleep Disorders, 3rd edition criteria, with a history of disease diagnosis >3 months prior to the Screening Visit
  • The participant is ≥18 and ≤64 years of age at the Screening Visit

Ki nem vehet részt

  • The participant has previously been enrolled in this trial
  • The participant has previously been dosed with Lu AH69593
  • The participant has participated in a clinical trial <30 days prior to the Screening Visit
  • The participant has worked shifts, including night duty, or has travelled across >3 time zones <2 weeks prior to the first dose of IMP
  • The participant has had a clinically significant illness from which he/she recovered <4 weeks prior to the first dose of IMP; Specifically for Participants in trial Part B and C:
  • The participant has any other disorder for which the treatment takes priority over treatment of narcolepsy or is likely to interfere with trial treatment or impair treatment compliance
  • The participant has a current medical disorder, other than NT1, associated with excessive daytime sleepiness (EDS); Note: Other protocol-defined inclusion and exclusion criteria may apply
  • The participant has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin or adequately treated cervical intraepithelial neoplasia, that has not been in remission for >5 years prior to the first dose of investigational medicinal product (IMP)
  • For all participants in any trial Part (A, B, C and D):
  • The participant is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not willing to use adequate contraceptive methods
  • The participant trains/exercises intensively, for example, for a marathon or triathlon, or at a competitive level; Specifically for participants in trial Part A, B and D:
  • The participant is at significant risk of suicide based on medical history, mental status, investigator judgement, or the C-SSRS answer of 'yes' to suicidal ideation question 4 or 5 or 'yes' to suicidal behaviour, within the last 6 months on the C-SSRS at the Screening Visit or 'Since last visit' at the Baseline Visit Day -1; Specifically for participants in trial Part C:

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 64 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of the trial is to determine if Lu AH69593 is safe and well tolerated. The trial will also look at how the body processes Lu AH69593 with and without food.

A vizsgálat 4 csoportja

  • Part A (Single Ascending Dose [SAD] in Healthy Participants): Lu AH69593 or PlaceboA vizsgált kezelés

    Participants will receive single oral dose of Lu AH69593 or placebo.

    Kezelés: Lu AH69593 és Placebo

  • Part B (Multiple Ascending Dose [MAD] in Healthy Participants): Lu AH69593 or PlaceboA vizsgált kezelés

    Participants will receive Lu AH69593 or placebo orally for 10 days.

    Kezelés: Lu AH69593 és Placebo

  • Part C (MAD in Participants With Narcolepsy Type 1 [NT1]): Lu AH69593A vizsgált kezelés

    Participants will receive Lu AH69593 orally for 84 days.

    Kezelés: Lu AH69593

  • Part D (Food Effect in Healthy Participants): Lu AH69593A vizsgált kezelés

    Participants with receive two single oral doses of Lu AH69593 in fasting or fed condition.

    Kezelés: Lu AH69593

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single- and Multiple-ascending-dose Trial Investigating Safety, Tolerability, and Pharmacokinetics of Lu AH69593 in Healthy Participants, Including Open-label Cohorts to Explore Pharmacodynamic Properties in Participants With Narcolepsy, and Food Effect in Healthy Participants
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07613710: ki vehet részt
A regiszteradat frissítve
2026. augusztus 12.